In this issue of EMBO J, using a combination of TRPC-deficient mouse models (Trpc1/4/5/6−/− and Trpc5−/−) and ad-hoc pharmacological tools, Bröker-Lai et al, bring overwhelming evidence that TRPC5 is highly expressed in CCs and its functional loss leads to a defective counter-regulation to insulin-evoked hypoglycemia due to the lack of increased plasma adrenaline (Bröker-Lai et al, 2024). Here, TRPC1 is linked to Hypoglycemia.